Preclinical studies have demonstrated that HCC xenografts with high FSP1 expression exhibit reduced sensitivity to GPX4 inhibitors; however, simultaneous targeting of FSP1 markedly restores tumor vulnerability, underscoring the therapeutic potential of this pathway. Here, GPX4 is linked to neoplasm.